

AMENDMENTS TO THE CLAIMS

1. **(Currently amended)** A process for amplifying TALL-104 lymphocytes in a homogeneous culture system within a multi-chamber stack comprising:

adding into the multi-chamber stack an inoculum of at least 0.7×10^6 TALL-104 cells/ml in an initial volume from 1/10 to 1/6 of the multi-chamber stack volume capacity and the same volume of fresh antibiotic-free complete medium;

amplifying the cell number by adding a complete medium volume corresponding to the volume contained in the multi-chamber stack every 3-5 days; and

harvesting ~~reecovering~~ at least 1×10^9 TALL-104 cells grown in homogeneous conditions.

2. **(Canceled)**

3. **(Canceled)**

4. **(Canceled)**

5. **(Previously presented)** The process as claimed in claim 1, wherein said process for amplifying TALL-104 lymphocytes is preceded by a process of pre-expansion in a flask until obtaining a number of cells in an amount from 3×10^8 to 4×10^8 .

6. **(Currently amended)** The process as claimed in claim 1, wherein the cellular density of the inoculum is 0.75×10^6 cells/ml and, at the harvesting step~~harvest time~~, the density is lower than 2×10^6 cells/ml.

7. **(Previously presented)** The process as claimed in claim 1, wherein the multi-chamber stack is a 10-chamber unit.

8. **(Previously presented)** The process as claimed in claim 1, wherein said TALL-104 lymphocytes are genetically modified.

9. **(Canceled)**

10. **(Previously presented)** The process as claimed in Claim 1, wherein the complete culture medium in the multi-chamber stack amplification phase also comprises a maximum of 10% human serum and interleukin in a concentration from 80 to 120 IU/ml.

11. **(Previously presented)** The process as claimed in claim 10, wherein interleukin-2 is added to the cell culture every 48-90 hrs.

12. **(Canceled)**

13. **(Currently amended)** A process for the preparation of frozen bags of TALL-104 lymphocytes in an amount of at least 1×10^9 cells comprising:

- a. recovering at least 1×10^9 TALL-104 cells grown in a homogeneous culture system in a multi-chamber stack according to claim 1;
- b. centrifuging the TALL-104 cells; and
- c. collecting the TALL-104 cells into frozen bags; and
- d. freezing the bags.

14. **(Previously presented)** The process as claimed in claim 13, wherein the bags are sealed transversally to a bag filling collet at least in two points to create at least a sampling chamber containing a cell culture volume ranging from 0.1 to 1 ml, physically separated from the culture contained in the bag to perform quality controls.

15. **(Previously presented)** A process for the preparation of a therapeutic dose of at least 1×10^9 TALL-104 lymphocytes in a homogeneous culture system comprising using the process according to Claim 1.

16.-24. **(Canceled)**

25. **(Previously presented)** The process as claimed in claim 10 wherein said complete culture medium comprises 4-6% human serum.

26. **(Previously presented)** A process according to claim 10, wherein said TALL-104 lymphocytes are genetically modified.

27. **(Canceled)**

28. **(Previously presented)** The process of claim 15, wherein the complete culture medium in the multi-chamber stack amplification phase also comprises a maximum of 10% human serum and interleukin in a concentration from 80 to 120 IU/ml.